Y:\Rankin\Yiren\paper figure and manuscript\Cancer Research\second revised version\supplementary figure 5.tif

**Supplementary Fig.S5. Kidney cancer ccRCC patient information and sAXL in sensitizing PDX tumor to TKI therapy.** (A) Timeline diagnosis and therapy for patient RCC054. (B) Sequencing of VHL in NCI597326-PDX tumor showing a VHL deletion mutation at nucleotide 403. (C) H&E staining of NCI597326 tumor demonstrated that histological features of clear cell renal cell carcinoma. (D) Schematic description of sAXL and pazopanib (PA) for established NCI597326-PDX treatment scheduling (*upper*) and tumor weight (*lower*). Data represent the averages ± SD. \*p < 0.05 and \*\*\*p < 0.001. (E) Sequencing of VHL in NCI961994-PDX tumor showing a VHL deletion mutation at nucleotide 403. (F) H&E staining of NCI961994 tumor demonstrated that histological features of clear cell renal cell carcinoma.